(Q33748979)

English

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis (English)

1 reference

Europe PubMed Central

29 July 2017

0 references

author name string

A Seckinger

1

1 reference

Europe PubMed Central

29 July 2017

T Meissner

2

1 reference

Europe PubMed Central

29 July 2017

J Moreaux

3

1 reference

Europe PubMed Central

29 July 2017

H Goldschmidt

4

1 reference

Europe PubMed Central

29 July 2017

G M Fuhler

5

1 reference

Europe PubMed Central

29 July 2017

A Benner

6

1 reference

Europe PubMed Central

29 July 2017

M Hundemer

7

1 reference

Europe PubMed Central

29 July 2017

T Rème

8

1 reference

Europe PubMed Central

29 July 2017

J D Shaughnessy

9

1 reference

Europe PubMed Central

29 July 2017

B Barlogie

10

1 reference

Europe PubMed Central

29 July 2017

U Bertsch

11

1 reference

Europe PubMed Central

29 July 2017

J Hillengass

12

1 reference

Europe PubMed Central

29 July 2017

A D Ho

13

1 reference

Europe PubMed Central

29 July 2017

V Pantesco

14

1 reference

Europe PubMed Central

29 July 2017

A Jauch

15

1 reference

Europe PubMed Central

29 July 2017

J De Vos

16

1 reference

Europe PubMed Central

29 July 2017

J F Rossi

17

1 reference

Europe PubMed Central

29 July 2017

T Möhler

18

1 reference

Europe PubMed Central

29 July 2017

B Klein

19

1 reference

Europe PubMed Central

29 July 2017

D Hose

20

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

31 August 2009

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

28

1 reference

Europe PubMed Central

29 July 2017

44

1 reference

Europe PubMed Central

29 July 2017

3866-3879

1 reference

Europe PubMed Central

29 July 2017

describes a project that uses

0 references

0 references

https://scigraph.springernature.com/pub.10.1038/onc.2009.257

0 references

Induction of angiogenesis by normal and malignant plasma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Expression of genes for bone morphogenetic proteins BMP-2, BMP-4 and BMP-6 in various parts of the human skeleton

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Adult mesenchymal stem cells for tissue engineering versus regenerative medicine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Microarray-based understanding of normal and malignant plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Signal transduction of bone morphogenetic protein receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Survival and proliferation factors of normal and malignant plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Heparan sulfate is required for bone morphogenetic protein-7 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

How cells read TGF-beta signals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Staging and kinetics of multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

21 June 2018

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

21 January 2018

Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

21 January 2018

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

21 January 2018

The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

21 January 2018

Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

21 January 2018

Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844406

30 October 2018

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

31 March 2020

Signal transduction by bone morphogenetic proteins

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

31 March 2020

Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.257

31 March 2020

Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/19718049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19718049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/ONC.2009.257

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33748979&oldid=1608322816"